AUA 2022 - American Urological Association Annual Meeting
May 13 - May 16, 2022 | New OrleansLAUS
LARVOL is not affiliated with American Urological Association Annual Meeting and all trademarks, logos, and brand names are property of their respective owners
Showing 77 abstracts linked to Trials
Interim analysis NCT04046094: IV Vitamin C With Chemotherapy for Cisplatin Ineligible Bladder Cancer Patients (CI-MIBC)
Plenary: Friday Morning: Late-Breaking Abstract: PLLBA-01: Final clinical results of pivotal trial of IL-15R&[alpha]Fc superagonist N-803 with BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) CIS and Papillary Cohorts
Niraparib with Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer: Results from the Phase 2 QUEST Study
Plenary: Friday Morning: Late-Breaking Abstract: PLLBA-02: Impact of 18F-rhPSMA-7.3 PET on upstaging of patients with prostate cancer recurrence: Results from the prospective, phase 3, multicenter, SPOTLIGHT study
Disease-Free Survival With Longer Follow-Up From the CheckMate 274 Trial of Adjuvant Nivolumab in Patients After Surgery for High-Risk Muscle-Invasive Urothelial Carcinoma
Overall Survival in Patients with Metastatic Hormone-Sensitive Prostate Cancer Treated with Enzalutamide or Placebo Plus Androgen Deprivation Therapy Who Had Prior Local Therapy: Post Hoc Analysis of the Phase 3 ARCHES Trial
Oral Relugolix for Androgen Deprivation Therapy in Advanced Prostate Cancer: Pooled Safety Analyses from Randomized Controlled Studies
Site-specific early response patterns in advanced RCC patients treated with Nivolumab and Ipilimumab compared with Sunitinib therapy
Comparison of clinical outcomes between androgen deprivation therapy with up-front abiraterone and bicalutamide for Japanese patients with LATITUDE high-risk prostate cancer in a real-world multicenter analysis
Oral Relugolix for Androgen Deprivation Therapy in Advanced Prostate Cancer: Detailed Safety Analysis from the Randomized Phase 3 HERO Study
A Phase 1/2 Study of Rapamycin and Cisplatin/Gemcitabine for Treatment of Patients (pts) With Muscle-Invasive Bladder Cancer (NCT01938573)
Efficacy and Safety of Darolutamide in Nonmetastatic Castration-resistant Prostate Cancer Patients With and Without Prior Local Therapy With Radical Prostatectomy or Radiotherapy
Two-Year Efficacy Follow-Up of a Phase I trial of Intravesical Bacillus Calmette-Guérin Combined with Intravenous Pembrolizumab in Recurrent or Persistent High-Grade Non-Muscle-Invasive Bladder Cancer after Previous Bacillus Calmette-Guérin Treat
A Phase II Study of Check Point Inhibitor; Durvalumab (MEDI4736) for Bacillus Calmette-Guerin Unresponsive Carcinoma in Situ of the Bladder
Impact of disease status heterogeneity of the STAMPEDE trial arm J population on oncological outcomes in high-risk nonmetastatic prostate cancer